Summary
- Biogen brings back to life its Alzheimer’s drug Aducanumab.
- Share price substantially recovers but too soon to know if Aducanumab works.
- Even if it gets FDA approved, will it be effective enough to become a blockbuster?
- Will it get tangled up in the drug pricing issue?
Last week, Biogen (NASDAQ:BIIB) shocked the biotech community with a dramatic announcement that Aducanumab, its failed treatment for Alzheimer's disease, looks like it was a success after all. This prompted a substantial recovery in Biogen's share price, although it is yet to get back to $300. There have been several articles in Seeking Alpha which advise caution about the current situation. Here I add to the list of reasons for thinking before buying.
FDA approvals versus what's useful
The FDA is a tough hurdle. To get a drug approved, you need to show a significant effect of the drug. Getting through the FDA maze often involves some pretty arcane stuff to demonstrate a significant effect. Lane Simonian's article makes this point well for the reversal by Biogen concerning its failed, and now possibly successful Alzheimer's treatment. Having said that, it seems like the FDA may be sympathetic to approving a drug that treats Alzheimer's disease progression as opposed to ameliorating its symptoms. Alzheimer's is a tough condition for the individual and a huge problem for society.
It is all about metrics
For the FDA, success is all about being able to measure a feature(s) of the disease accurately and then tying your trial endpoints to improvement in those features. If your measure is "how did you feel today?", then you are never going to get the drug approved. This is why increasingly technical metrics are keenly sought and why often advances come as a result of new measuring technology. Of course, a lot of this comes back to molecular markers, but new imaging technology is also valuable for visualizing physical changes.
The Alzheimer's plaque model... be careful what you measure
PET imaging made it possible to measure amyloid plaques in a non-invasive way, and hence investigate drugs that reduced plaque.
Christiana Friedman's Seeking Alpha article helps clarify what is being measured and how it might be (or not be) relevant to a drug for treating Alzheimer's. From her perspective, removing plaque may be a side effect of treatment and not at the core.
She acknowledges that as well as reducing amyloid-plaques, it also seems as if Aducanumab slows cognitive impairment, which indicates that Aducanumab is addressing a key part of Alzheimer's disease progression. However, she makes the point that other beta-amyloid plaque reducing drugs by Novartis (NYSE:NVS), Amgen (NADAQ:AMGN), Merck (NYSE:MRK) and Roche (OTCQX:RHHBY), have failed to prevent cognitive impairment, so she wonders if the beta-amyloid plaque hypothesis is a consequence of rather than being central to Alzheimer's disease.
So she cautions about the possibility that other failed plaque removing drugs from other companies will get a life again.

